** Shares in Bavarian Nordic BAVA.CO rise around 12% to their highest since end February after the Danish biotech's Q1 revenue came in above market expectations
** Its Q1 revenue was DKK 1,347 million ($203.08 million) against the company-compiled consensus estimate of DKK 995 million
** Kempen says the revenue was boosted by few larger existing public preparedness orders recorded in the first quarter
** If gains hold, the stock will see its biggest one-day rise since August 2024; it is at the top of pan-European STOXX 600 .STOXX index
($1 = 6.6327 Danish crowns)
(Reporting by Elviira Luoma)
((Elviira.luoma@thomsonreuters.com))